IL2 and systemic lupus erythematosus: In clinical studies treatment of SLE patients with low dose IL-2 increased Tregs, decreased AICD and restored CTL responses along with a reduction of serum anti-dsDNA antibodies (von Spee-Mayer et al., 2016; He et al., 2016).